Company Filing History:

16 out of 940

Fujisawa Pharmaceutical Company, Ltd.

Years Active: 1983-2008

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7317009 - Pyrrolopyridazine derivatives (2008-01-08),

2. 7153854 - Pyrrolopyridazine derivatives (2006-12-26),

3. 6582351 - Imidazopyridinone derivatives and their use as phosphodiesterase inhibitors (2003-06-24),

4. 6384080 - Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase (2002-05-07),

5. 6069156 - Indole derivatives as cGMP-PDE inhibitors (2000-05-30),

6. 5780633 - Process for the preparation of indolizine derivatives (1998-07-14),

7. 5530019 - Indole derivatives useful as testosterone 5.alpha.-reductase inhibitors (1996-06-25),

8. 5334716 - Heterocyclic derivatives (1994-08-02),

9. 5312829 - Indole derivatives (1994-05-17),

10. 5283251 - Indole derivatives (1994-02-01),

11. 5212320 - Indole derivatives and their use for testosterone (1993-05-18),

12. 4963585 - Compound, WF11605 and derivative thereof (1990-10-16),

13. 4883800 - Quinazoline derivatives and process for their production (1989-11-28),

14. 4734419 - Quinazoline derivatives, compositions thereof and their use in treating (1988-03-29),

15. 4640915 - 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid derivatives (1987-02-03),

Title: Kozo Sawada: Innovator in Medicinal Chemistry

Introduction

Kozo Sawada is a prominent inventor based in Tsukuba, Japan. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on pyrrolopyridazine derivatives. With a total of 18 patents to his name, Sawada has established himself as a key figure in pharmaceutical research and development.

Latest Patents

Among his latest patents, Sawada has developed compounds related to pyrrolopyridazine derivatives. These inventions involve compounds of the formula (I) or their salts, which are defined in detail in the patent description. The compounds are noted for their potential use as medicaments, specifically in the treatment of PDE-IV or TNF-α mediated diseases. This research highlights his commitment to advancing therapeutic options for complex medical conditions.

Career Highlights

Throughout his career, Kozo Sawada has worked with notable companies in the pharmaceutical industry. He has been associated with Fujisawa Pharmaceutical Company, Ltd. and Astellas Pharma GmbH, where he has contributed to various innovative projects. His work has not only advanced the field of medicinal chemistry but has also had a lasting impact on the development of new treatments.

Collaborations

Sawada has collaborated with esteemed colleagues in his field, including Masashi Hashimoto and Hirokazu Tanaka. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kozo Sawada's contributions to medicinal chemistry and his extensive patent portfolio underscore his role as a leading inventor in the pharmaceutical industry. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com